Potential antagonism of tubulin-binding anticancer agents in combination therapies

Giulia Taraboletti, Gianluca Micheletti, Romina Dossi, Patrizia Borsotti, Michele Martinelli, Fabio Fiordaliso, Anderson J. Ryan, Raffaella Giavazzi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

ZD6126 is a vascular targeting agent, developed for the treatment of solid tumors. In vivo, ZD6126 is rapidly converted into the tubulin-binding agent N-acetylcolchinol. We have previously reported that in vitro N-acetylcolchinol disrupts microtubules and induces rapid changes in endothelial cell morphology, which in a tumor would lead to a rapid loss of tumor vessel integrity and subsequent extensive tumor necrosis. The aim of this study was to investigate the effect of cytotoxic antineoplastic drugs - cisplatin, doxorubicin, vincristine, paclitaxel, and docetaxel - on endothelial cell response to N-acetylcolchinol. We found that cisplatin and doxorubicin did not interfere with the ability of N-acetylcolchinol to cause morphologic changes in human umbilical vein endothelial cells, whereas vincristine showed additive effects. In contrast, the microtubule-stabilizing agents paclitaxel (1-10 μmol/L) and docetaxel (0.1-1 μmol/L) prevented the morphologic changes induced by N-acetylcolchinol in human umbilical vein endothelial cells. The effect was observed when cells were exposed to paclitaxel and N-acetylcolchinol together or when paclitaxel was given shortly before N-acetylcolchinol. Paclitaxel and N-acetylcolchinol interacted at the level of microtubule organization, as shown in immunofluorescence analysis of the cytoskeleton. The protective effect was reversible because 4 hours after paclitaxel wash out, cells recovered the sensitivity to N-acetylcolchinol. In vivo, pretreatment of mice with paclitaxel inhibited the vascular targeting activity of ZD6126 on newly formed vessels in the Matrigel plug assay and ZD6126-induced necrosis in tumors. These findings indicate that paclitaxel, depending on the timing and schedule of administration, can affect the vascular targeting activity of ZD6126, which may have an effect on the optimal scheduling of therapies based on the combined use of microtubule-stabilizing and microtubule-destabilizing agents.

Original languageEnglish
Pages (from-to)2720-2726
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number7
DOIs
Publication statusPublished - Apr 1 2005

Fingerprint

Tubulin
Antineoplastic Agents
Paclitaxel
Microtubules
docetaxel
Blood Vessels
Therapeutics
Human Umbilical Vein Endothelial Cells
Vincristine
Neoplasms
Doxorubicin
Cisplatin
Necrosis
Endothelial Cells
N-acetylcolchinol
Excipients
Cytoskeleton
Fluorescent Antibody Technique
Appointments and Schedules
N-acetylcochinol-O-phosphate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Potential antagonism of tubulin-binding anticancer agents in combination therapies. / Taraboletti, Giulia; Micheletti, Gianluca; Dossi, Romina; Borsotti, Patrizia; Martinelli, Michele; Fiordaliso, Fabio; Ryan, Anderson J.; Giavazzi, Raffaella.

In: Clinical Cancer Research, Vol. 11, No. 7, 01.04.2005, p. 2720-2726.

Research output: Contribution to journalArticle

Taraboletti, Giulia ; Micheletti, Gianluca ; Dossi, Romina ; Borsotti, Patrizia ; Martinelli, Michele ; Fiordaliso, Fabio ; Ryan, Anderson J. ; Giavazzi, Raffaella. / Potential antagonism of tubulin-binding anticancer agents in combination therapies. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 7. pp. 2720-2726.
@article{a2ada9985a1c47b3a12635ef74ca3ea9,
title = "Potential antagonism of tubulin-binding anticancer agents in combination therapies",
abstract = "ZD6126 is a vascular targeting agent, developed for the treatment of solid tumors. In vivo, ZD6126 is rapidly converted into the tubulin-binding agent N-acetylcolchinol. We have previously reported that in vitro N-acetylcolchinol disrupts microtubules and induces rapid changes in endothelial cell morphology, which in a tumor would lead to a rapid loss of tumor vessel integrity and subsequent extensive tumor necrosis. The aim of this study was to investigate the effect of cytotoxic antineoplastic drugs - cisplatin, doxorubicin, vincristine, paclitaxel, and docetaxel - on endothelial cell response to N-acetylcolchinol. We found that cisplatin and doxorubicin did not interfere with the ability of N-acetylcolchinol to cause morphologic changes in human umbilical vein endothelial cells, whereas vincristine showed additive effects. In contrast, the microtubule-stabilizing agents paclitaxel (1-10 μmol/L) and docetaxel (0.1-1 μmol/L) prevented the morphologic changes induced by N-acetylcolchinol in human umbilical vein endothelial cells. The effect was observed when cells were exposed to paclitaxel and N-acetylcolchinol together or when paclitaxel was given shortly before N-acetylcolchinol. Paclitaxel and N-acetylcolchinol interacted at the level of microtubule organization, as shown in immunofluorescence analysis of the cytoskeleton. The protective effect was reversible because 4 hours after paclitaxel wash out, cells recovered the sensitivity to N-acetylcolchinol. In vivo, pretreatment of mice with paclitaxel inhibited the vascular targeting activity of ZD6126 on newly formed vessels in the Matrigel plug assay and ZD6126-induced necrosis in tumors. These findings indicate that paclitaxel, depending on the timing and schedule of administration, can affect the vascular targeting activity of ZD6126, which may have an effect on the optimal scheduling of therapies based on the combined use of microtubule-stabilizing and microtubule-destabilizing agents.",
author = "Giulia Taraboletti and Gianluca Micheletti and Romina Dossi and Patrizia Borsotti and Michele Martinelli and Fabio Fiordaliso and Ryan, {Anderson J.} and Raffaella Giavazzi",
year = "2005",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-04-1616",
language = "English",
volume = "11",
pages = "2720--2726",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Potential antagonism of tubulin-binding anticancer agents in combination therapies

AU - Taraboletti, Giulia

AU - Micheletti, Gianluca

AU - Dossi, Romina

AU - Borsotti, Patrizia

AU - Martinelli, Michele

AU - Fiordaliso, Fabio

AU - Ryan, Anderson J.

AU - Giavazzi, Raffaella

PY - 2005/4/1

Y1 - 2005/4/1

N2 - ZD6126 is a vascular targeting agent, developed for the treatment of solid tumors. In vivo, ZD6126 is rapidly converted into the tubulin-binding agent N-acetylcolchinol. We have previously reported that in vitro N-acetylcolchinol disrupts microtubules and induces rapid changes in endothelial cell morphology, which in a tumor would lead to a rapid loss of tumor vessel integrity and subsequent extensive tumor necrosis. The aim of this study was to investigate the effect of cytotoxic antineoplastic drugs - cisplatin, doxorubicin, vincristine, paclitaxel, and docetaxel - on endothelial cell response to N-acetylcolchinol. We found that cisplatin and doxorubicin did not interfere with the ability of N-acetylcolchinol to cause morphologic changes in human umbilical vein endothelial cells, whereas vincristine showed additive effects. In contrast, the microtubule-stabilizing agents paclitaxel (1-10 μmol/L) and docetaxel (0.1-1 μmol/L) prevented the morphologic changes induced by N-acetylcolchinol in human umbilical vein endothelial cells. The effect was observed when cells were exposed to paclitaxel and N-acetylcolchinol together or when paclitaxel was given shortly before N-acetylcolchinol. Paclitaxel and N-acetylcolchinol interacted at the level of microtubule organization, as shown in immunofluorescence analysis of the cytoskeleton. The protective effect was reversible because 4 hours after paclitaxel wash out, cells recovered the sensitivity to N-acetylcolchinol. In vivo, pretreatment of mice with paclitaxel inhibited the vascular targeting activity of ZD6126 on newly formed vessels in the Matrigel plug assay and ZD6126-induced necrosis in tumors. These findings indicate that paclitaxel, depending on the timing and schedule of administration, can affect the vascular targeting activity of ZD6126, which may have an effect on the optimal scheduling of therapies based on the combined use of microtubule-stabilizing and microtubule-destabilizing agents.

AB - ZD6126 is a vascular targeting agent, developed for the treatment of solid tumors. In vivo, ZD6126 is rapidly converted into the tubulin-binding agent N-acetylcolchinol. We have previously reported that in vitro N-acetylcolchinol disrupts microtubules and induces rapid changes in endothelial cell morphology, which in a tumor would lead to a rapid loss of tumor vessel integrity and subsequent extensive tumor necrosis. The aim of this study was to investigate the effect of cytotoxic antineoplastic drugs - cisplatin, doxorubicin, vincristine, paclitaxel, and docetaxel - on endothelial cell response to N-acetylcolchinol. We found that cisplatin and doxorubicin did not interfere with the ability of N-acetylcolchinol to cause morphologic changes in human umbilical vein endothelial cells, whereas vincristine showed additive effects. In contrast, the microtubule-stabilizing agents paclitaxel (1-10 μmol/L) and docetaxel (0.1-1 μmol/L) prevented the morphologic changes induced by N-acetylcolchinol in human umbilical vein endothelial cells. The effect was observed when cells were exposed to paclitaxel and N-acetylcolchinol together or when paclitaxel was given shortly before N-acetylcolchinol. Paclitaxel and N-acetylcolchinol interacted at the level of microtubule organization, as shown in immunofluorescence analysis of the cytoskeleton. The protective effect was reversible because 4 hours after paclitaxel wash out, cells recovered the sensitivity to N-acetylcolchinol. In vivo, pretreatment of mice with paclitaxel inhibited the vascular targeting activity of ZD6126 on newly formed vessels in the Matrigel plug assay and ZD6126-induced necrosis in tumors. These findings indicate that paclitaxel, depending on the timing and schedule of administration, can affect the vascular targeting activity of ZD6126, which may have an effect on the optimal scheduling of therapies based on the combined use of microtubule-stabilizing and microtubule-destabilizing agents.

UR - http://www.scopus.com/inward/record.url?scp=17644395253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644395253&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1616

DO - 10.1158/1078-0432.CCR-04-1616

M3 - Article

C2 - 15814654

AN - SCOPUS:17644395253

VL - 11

SP - 2720

EP - 2726

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -